Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143674 | 0.97 | LMNA (0.47) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL345625 | 0.97 | LMNA (0.47) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL86666 | 0.97 | LMNA (0.47) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL345694 | 0.92 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL2186144 | 0.92 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL345693 | 0.92 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL8702996 | 0.90 | LMNA (0.44) | LMNANPSR1KMT2AMEN1KDM1A | |
| SCHEMBL29285446 | 0.88 | LMNA (0.45) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL4093277 | 0.87 | NPSR1 (0.44) | LMNANPSR1KMT2AMEN1KDM1A | |
| SCHEMBL7918528 | 0.86 | HCRTR2 (0.49) | KMT2AMEN1KDM1AAPPHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-111393414-B | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-112119080-B | Imidazo [4,5-C ] pyridine compounds as LSD-1 inhibitors | 密歇根大学董事会 | 2023-07-11 | — | — | CN | disclosed |
| CN-101821251-A | Chiral cis-imidazolines | HOFFMANN LA ROCHE | 2010-09-01 | — | — | CN | disclosed |
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1475373-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1471060-A1 | 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists | Ajinomoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6528504-B2 | Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. | AJINOMOTO CO., INC. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | AJINOMOTO CO., INC. (JP) | 2002-07-25 | — | — | US | disclosed |
| EP-1142884-A1 | OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | LMNA 3367/4885NPSR1 1088/4885KMT2A 1693/4885 |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | LMNA 3263/4885NPSR1 1317/4885KMT2A 1104/4885 |
| US-20020099047-A1 | Oxazepine derivatives and medicine containing the same | CACNG5, GRIK5, KCNB1 | LMNA 3631/4885NPSR1 910/4885KMT2A 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.